Drug Profile
Aviptadil - Relief Therapeutics Holdings
Alternative Names: aviptadil acetate; DasKloster 1000; DasKloster 1000-01; DasKloster 1000-02; DasKloster 1000-03; DasKloster 1000-04; DK-1000; RLF-100; RLF-100 IV; RLF-100TM; SamiAIR™; SamiVIP™; SAMIVIR™; Vasoactive intestinal peptide; Vasoactive intestinal peptide hybrid; VIP; ZYESAMILatest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator mondoBIOTECH
- Developer Centurion Pharma; Lung Rx; mondoBIOTECH; NRx Pharmaceuticals; Quantum Leap Healthcare Collaborative; RELIEF THERAPEUTICS Holding; University of Freiburg
- Class Anti-inflammatories; Antifibrotics; Antivirals; Gastrointestinal hormones; Neuropeptides; Peptide hormones
- Mechanism of Action Vasoactive intestinal peptide replacements; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Registered SARS-CoV-2 acute respiratory disease
- Phase III Pulmonary sarcoidosis
- Phase II COVID 2019 infections
- Discontinued Adult respiratory distress syndrome; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
Most Recent Events
- 18 Jan 2024 Cantonal Hosptal, Baselland terminates a phase II trial for COVID-2019 infections in Switzerland due to difficulties recruiting participants as there are very few hospitalized COVID patients and even after continuous screening none of the patients met the eligibility criteria (Inhalation) (NCT04536350)
- 19 May 2023 Updated efficacy data from the phase IIb/III COVID-AIV trial in SARS-COV-2 acute respiratory disease presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
- 03 Feb 2023 NeuroRx terminates the AVICOVID-2 phase IIb/III trial in SARS-COV-2 acute respiratory disease (In children, In adults, In adolescents, In the elderly) in USA (Inhalation) due to sponsor's decision (NCT04360096)